Invivyd's (IVVD) Buy Rating Reaffirmed at HC Wainwright

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $5.00 target price on the stock.

Separately, D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday.

Invivyd Stock Performance

Shares of NASDAQ:IVVD traded up $0.06 during trading on Thursday, hitting $0.77. The company's stock had a trading volume of 1,603,305 shares, compared to its average volume of 4,535,275. The stock's 50-day moving average price is $0.75 and its two-hundred day moving average price is $0.76. The company has a market capitalization of $92.01 million, a PE ratio of -0.64 and a beta of 0.63. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Invivyd had a negative return on equity of 165.24% and a negative net margin of 389.01%. On average, equities analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently modified their holdings of the company. Mithril II GP LP acquired a new position in shares of Invivyd during the fourth quarter valued at $4,981,000. Deutsche Bank AG raised its stake in shares of Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after buying an additional 227,463 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after buying an additional 391,617 shares during the period. Two Sigma Investments LP boosted its stake in Invivyd by 125.3% during the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock valued at $163,000 after buying an additional 204,188 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock worth $135,000 after acquiring an additional 282,100 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.